(Q77959634)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

review article

1 reference

title

A risk-benefit assessment of abciximab in angioplasty (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

N S Kleiman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

publication date

1 January 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

43-57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9935276%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00002018-199920010-00005

9 December 2019

exact match

0 references

cites work

The restenosis paradigm revisited: an alternative proposal for cellular mechanisms

1 reference

12 December 2020

Cell adhesion and angiogenesis

1 reference

12 December 2020

Thrombin-antithrombin III complexes in type II diabetes mellitus

1 reference

12 December 2020

In Vivo Platelet Activation in Diabetes Mellitus

1 reference

12 December 2020

Further evidence that glycoprotein IIb-IIIa mediates platelet spreading on subendothelium

1 reference

12 December 2020

Thromboxane biosynthesis and platelet function in type II diabetes mellitus

1 reference

12 December 2020

Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry

1 reference

12 December 2020

Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate

1 reference

12 December 2020

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

1 reference

12 December 2020

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

12 December 2020

Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model

1 reference

12 December 2020

Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles

1 reference

12 December 2020

1 reference

12 December 2020

Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty

1 reference

12 December 2020

The pathogenesis of a coronary thrombus

1 reference

12 December 2020

Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors

1 reference

12 December 2020

The platelet function defect of cardiopulmonary bypass

1 reference

12 December 2020

Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).

1 reference

12 December 2020

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

1 reference

12 December 2020

Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty

1 reference

12 December 2020

Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complicatio

1 reference

12 December 2020

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

12 December 2020

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

12 December 2020

Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction

1 reference

12 December 2020

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

12 December 2020

Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.

1 reference

12 December 2020

Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators

1 reference

12 December 2020

Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention

1 reference

12 December 2020

Increased Risk of Non-Q Wave Myocardial Infarction After Directional Atherectomy Is Platelet Dependent: Evidence From the EPIC Trial

1 reference

12 December 2020

Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions

1 reference

12 December 2020

Prognostic implication of creatine kinase elevation following elective coronary artery interventions.

1 reference

12 December 2020

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators

1 reference

12 December 2020

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

1 reference

12 December 2020

7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

1 reference

12 December 2020

Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II

1 reference

12 December 2020

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

12 December 2020

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

12 December 2020

Partial reversal of heparin anticoagulation by intravenous protamine in abciximab-treated patients undergoing percutaneous intervention

1 reference

12 December 2020

Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels

1 reference

12 December 2020

Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

1 reference

12 December 2020

Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI)

1 reference

12 December 2020

Rapid reversal of no-reflow using Abciximab after coronary device intervention

1 reference

12 December 2020

"Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty

1 reference

12 December 2020

Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicenter Trial fn1fn1This study was suppported by a grant from Centocor, Inc

1 reference

12 December 2020

Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery

1 reference

12 December 2020

Final results of the Balloon vs Optimal Atherectomy Trial (BOAT)

1 reference

12 December 2020

Abciximab and excessive bleeding in patients undergoing emergency cardiac operations

1 reference

12 December 2020

Predictors of Restenosis After Coronary Stent Implantation

1 reference

12 December 2020

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

12 December 2020

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

12 December 2020

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators

1 reference

12 December 2020

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

12 December 2020

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

12 December 2020

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

12 December 2020

Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro)

1 reference

12 December 2020

Regimen lowers rate of coronary events in diabetes

1 reference

12 December 2020

Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins

1 reference

12 December 2020

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

12 December 2020